Trial | Arms | N | Population | Age and PS 0-1 | Stage | LDH | IPI | RT |
---|---|---|---|---|---|---|---|---|
SWOG 8736 | CHOP x 8 | 201 | WF groups D-J (DLBCL 75%); stage I to II non-bulky | > 60y = 49% 0-1 = 96% | II 33% | ↑ 19% | 0-1 = 71% | No RT |
CHOP x 3 + RT | 200 | >60y = 50% 0-1 = 97% | II 32% | ↑ 20% | 0-1 = 74% | IFRT 40-55 Gy | ||
ECOG 1484 | CHOP x 8 | 112 | WF H-J (DLBCL 83%); stage I bulky to II; complete responders to CHOP only | Median 60y 0-1 = 93% | II 70% E 52%, B20% | NA | NR | No RT |
CHOP x 8 + RT | 103 | Median 58y 0-1 = 96% | II 68% E 45% B22% | NA | NR | IFRT 30 Gy | ||
GELA LNH 93-1 | ACVBP + CT | 318 | WF H-J or anaplastic according to uKC (DLBCL 81%); 15-60y; aaIPI = 0†; stages I to II | Median 46y 0-1 = 100% | II 32% E 46% | ↑ 3% | 0 = 96%† | No RT |
CHOP x 3 + RT | 329 | Median 47y 0-1 = 100% | II 32% E 52% | ↑ 3% | 0 = 95%† | IFRT 40 Gy | ||
GELA LNH 93-4 | CHOP x 4 | 277 | WF H-J or anaplastic according to uKC (DLBCL 80%); >60y; aaIPI = 0†; stages I to II | Median 69y 0-1 = 99% | II 32% Bu 8% | ↑ 2% | 0 = 95%† | No RT |
CHOP x 4 + RT | 299 | Median 68y 0-1 = 99% | II 34% Bu 9% | ↑ 3% | 0 = 95%† | IFRT 40 Gy |